The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized, Small), Scale of Operation (Preclinical / Clinical and Commercial), Stage of Bioprocess (Upstream and Downstream), Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    June 2021

  • Pages
    191

  • View Count
    829

Example Insights

Continuous-and-Semi-Continuous-Bioprocessing-Market-Context Continuous-and-Semi-Continuous-Bioprocessing-Market-Distribution-by-Type-of-Secondary-Bioprocessing-Involved 	Continuous-and-Semi-Continuous-Bioprocessing-Market-Distribution-by-Scale-of-Operation
Continuous-and-Semi-Continuous-Bioprocessing-Market-Distribution-by-Location Continuous-and-Semi-Continuous-Bioprocessing-Market-Distribution-by-Stage-of-BioProcess Continuous-and-Semi-Continuous-Bioprocessing-Market-Continuous-Manufacturing-Equipment-Providers
Continuous-and-Semi-Continuous-Bioprocessing-Market-Cost-Saving-Potential 	Continuous-and-Semi-Continuous-Bioprocessing-Market-Capacity-Analysis Continuous-and-Semi-Continuous-Bioprocessing-Market-Future-Forecast

 

Overview

For years, the batch and fed-batch processing technique has been the only available solution for biomanufacturing. However, this method is plagued with several shortcomings, such as process inefficiencies, high risk of human errors and low production speeds. Modern biopharmaceuticals demand faster, and more efficient technologies, preferably with seamless transition into succeeding steps; the primary goal, in this regard, being the preservation of sterility. In other words, a continuous bioprocessing approach is better suited to the needs of the aseptic manufacturing paradigm that is required for biologics. In this context, the introduction of perfusion bioreactors in the late 1980s was a revolutionary development within the industry. Presently, there are multiple available technologies that are capable of supporting continuous downstream (including clarification / centrifugation, filtration, and chromatography steps) and upstream bioprocesses (which include cell line development and other pre-fermentation steps). A significant number of biopharmaceutical companies, especially certain big pharma players and large contract manufacturing service providers, claim to have already adopted, or are considering installing, continuous bioprocessing technologies, such as perfusion bioreactors, continuous chromatography and continuous filtration equipment. Continuous flow systems have been proven to address a number of challenges associated with traditional bioprocessing; for instance, they facilitate the lowering of manufacturing costs (by 60%) reduction in buffer use (by 30-50%) optimization of resin consumption (by 70%) in chromatography columns, reduction in product change over time (by 90%) improvement of  product consistency across different batches (by 50%) minimizing facility footprints (by 50-70%), reduction in operating expenditure (by 90%) and seamless scale up. All the aforementioned advantages eventually serve to improve overall productivity (by 300-400%).

The current focus of the users of this novel technology is primarily on upgrading individual operations to the continuous mode; as indicated earlier, some companies have already established bioprocessing lines with multiple continuous processes. Cost, (end product) quality, processing speed and operational flexibility are some of the primary driving factors of the gradual shift to continuous bioprocessing. The COVID-19 pandemic has also contributed to accelerating the adoption of continuous flow systems. Some of the existing challenges in this field include complexities related to defining continuous processes (especially those upstream to the fermentation step), and aligning the available equipment to operate as per current GMP requirements. Although an end-to-end continuous bioproduction line is still several years away, we believe that the opportunity for both innovators and service providers engaged in this domain is likely to grow in the foreseen future.

Scope of the Report

The “Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized and Small), Scale of Operation (Preclinical / Clinical and Commercial), Stage of Bioprocess (Upstream and Downstream), Geographical Regions (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the companies having continuous and semi-continuous bioprocessing capabilities. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the companies that have adopted continuous and semi-continuous bioprocessing, including analyses based on a number of relevant parameters, such as year of establishment, company size, type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters, locations of continuous and semi-continuous bioprocessing facilities of innovators, locations of continuous and semi-continuous bioprocessing facilities of contract service providers, type of facility (modular and conventional), type of bioreactor (single-use and stainless steel), stage of bioprocess (upstream and downstream), primary continuous and semi-continuous bioprocessing (continuous cell culture, continuous clarification / harvesting, continuous purification, process analytical technology and others), secondary continuous and semi-continuous bioprocessing (N-1 stage perfusion, N stage perfusion, continuous concentrated fed-batch, continuous cell retention, continuous centrifugation, continuous chromatography and continuous viral filtration), types of biologics manufactured (antibodies, proteins / peptides, vectors, enzymes and others) and details on the continuous and semi-continuous production capacity.
  • Tabulated profiles of the key players offering a wide range of services for the continuous and semi-continuous bioprocessing of products across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.
  • Key initiatives taken by the leading pharmaceutical companies, taking into consideration both partnered as well as in-house projects.
  • A case study to depict the overall landscape of the continuous and semi-continuous bioprocessing equipment providers, based on a number of parameters, such as type of equipment, type of manufacturing process (continuous and batch-continuous), stage of bioprocess (upstream process and downstream process) and scale of operation (preclinical / clinical and commercial).
  • An insightful analysis highlighting the cost saving potential associated with the adoption of continuous and semi-continuous bioprocessing technologies.
  • A detailed analysis to estimate the global, continuous upstream bioprocessing capacity based on the capacities of various industry stakeholders. The study includes the distribution of capacity, based on company size (small, mid-sized and large), type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location  of continuous and semi-continuous bioprocessing facilities (North America, Europe and Asia-Pacific).

One of the key objectives of the report was to estimate the current market size and the growth opportunities in the continuous and semi-continuous bioprocessing market, over the next decade. Based on different parameters, such as global biopharmaceutical market, cost of goods sold, manufacturing cost of biologics, share of API manufacturing, upstream and downstream costs in biologics manufacturing, we have provided informed estimates on the evolution of the market for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:

  • Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)
  • Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)
  • Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Which are the leading contract manufacturers offering expertise in continuous bioprocessing?
  • Which are the leading innovators / drug developers with expertise in continuous bioprocessing?
  • In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
  • What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
  • What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the continuous and semi-continuous bioprocessing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to continuous bioprocessing technology. The chapter describes the historical evolution of continuous bioprocessing in the pharmaceutical industry. It features a brief overview of the regulatory landscape, the early adopters of this technology, opportunities and key challenges associated with the adoption of these techniques. The chapter also discusses the future perspectives of the continuous and semi-continuous bioprocessing market.

Chapter 4 provides an overview of the overall landscape of the companies with capabilities for continuous and semi-continuous bioprocessing, including information on around 60 players engaged in this domain. Additionally, it features an in-depth analysis of the companies, based on a number of parameters, such as year of establishment, company size, type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters, location of continuous and semi-continuous bioprocessing facilities of innovators, location of continuous and semi-continuous bioprocessing facilities of contract service providers, type of facility (modular and conventional), type of bioreactor (single-use and stainless steel), stage of bioprocess (upstream and downstream), primary continuous and semi-continuous bioprocessing (continuous cell culture, continuous clarification / harvesting, continuous purification, process analytical technology and others), secondary continuous and semi-continuous bioprocessing (N-1 stage perfusion, N stage perfusion, continuous concentrated fed-batch, continuous cell retention, continuous centrifugation, continuous chromatography and continuous viral filtration), types of biologics manufactured (antibodies, proteins / peptides, vectors, enzymes and others) and details on the continuous and semi-continuous production capacity.

Chapter 5 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in North America. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 6 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in Europe. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 7 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 8 highlights the key initiatives taken by the leading pharmaceutical companies (in terms of revenues generated), taking into consideration both partnered as well as in-house projects.

Chapter 9 is a case study providing information on more than 80 continuous manufacturing equipment for biologics. It features a detailed analysis based on the type of equipment, type of manufacturing process (continuous and batch-continuous) and stage of bioprocess (upstream process and downstream process) and the scale of operation (preclinical / clinical and commercial). Further, the chapter provides information on equipment provider(s) along with information on their year of establishment, company size, location of headquarters and key players in this domain.

Chapter 10 presents an insightful analysis of the cost saving potential associated with the adoption of continuous and semi-continuous bioprocessing technologies.

Chapter 11 features a detailed analysis of the global, continuous upstream bioprocessing capacity based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the company size (small, mid-sized and large), type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of continuous and semi-continuous bioprocessing facilities (North America, Europe and Asia-Pacific).

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the continuous and semi-continuous bioprocessing market till the year 2030. In order to provide an informed future outlook, our projections have been segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 13 is a summary of the overall report wherein we have mentioned all the key facts and figures described in the chapters. The chapter also highlights the important evolutionary trends that were identified during our research and are expected to influence the continuous and semi-continuous bioprocessing market in the future.

Chapter 14 contains the interview transcripts of the discussions held with key stakeholders engaged in this domain. In this study, we spoke to Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca), Ehsan Mahdinia (Assistant professor, Albany College of Pharmacy and Health Sciences) and Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences).

Chapter 15 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Continuous Bioprocessing
3.3. Continuous Processing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of the Technology
3.3.3. Anticipated Shift from Batch Processing
3.3.4. Advantages of Continuous Processing 
3.3.5. Key Challenges Associated with Continuous Processing
3.3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Continuous and Semi-Continuous Bioprocessing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Type of Manufacturer
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Company Size and Type of Manufacturer
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Innovators
4.2.8. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Contract Service Providers
4.2.9. Analysis by Type of Facility
4.2.10. Analysis by Type of Bioreactor
4.2.11. Analysis by Stage of Bioprocess
4.2.11.1. Primary Continuous and Semi-Continuous Bioprocessing
4.2.11.2. Secondary Continuous and Semi-Continuous Bioprocessing
4.2.12. Analysis by Types of Biologics Manufactured
4.2.13. Information on Production Capacity 

5. CONTINUOUS BIOPROCESSING IN NORTH AMERICA: COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.2.2. Recent Developments and Future Outlook

5.3. Biogen
5.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.3.2. Recent Developments and Future Outlook

5.4. Bristol-Myers Squibb
5.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.4.2. Recent Developments and Future Outlook

5.5. Sanofi Genzyme
5.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.5.2. Recent Developments and Future Outlook

6. CONTINUOUS BIOPROCESSING IN EUROPE: COMPANY PROFILES
6.1. Chapter Overview
6.2. FUJIFILM Diosynth Biotechnologies
6.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.2.2. Recent Developments and Future Outlook

6.3. Merck KGaA
6.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.3.2. Recent Developments and Future Outlook

6.4. Novasep
6.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.4.2. Recent Developments and Future Outlook

6.5. UCB Pharma
6.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.5.2. Recent Developments and Future Outlook

7. CONTINUOUS BIOPROCESSING IN ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Enzene Biosciences
7.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.2.2. Recent Developments and Future Outlook

7.3. WuXi Biologics
7.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.3.2. Recent Developments and Future Outlook

8. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS BIOPROCESSING CAPABILITIES
8.1. Chapter Overview
8.2. Continuous Manufacturing Initiatives of Leading Companies
8.2.1. AbbVie
8.2.1.1. Partnered Initiatives 
8.2.1.2. In-House Initiatives

8.2.2. Amgen
8.2.2.1. Partnered Initiatives
8.2.2.2. In-House Initiatives

8.2.3. Bristol-Myers Squibb
8.2.3.1. Partnered Initiatives
8.2.3.2. In-House Initiatives

8.2.4. GlaxoSmithKline
8.2.4.1. Partnered Initiatives
8.2.4.2. In-House Initiatives

8.2.5. Merck
8.2.5.1. Partnered Initiatives
8.2.5.2. In-House Initiatives

8.2.6. Novartis
8.2.6.1. Partnered Initiatives
8.2.6.2. In-House Initiatives

8.2.7. Pfizer
8.2.7.1. Partnered Initiatives
8.2.7.2. In-House Initiatives

8.2.8. Roche
8.2.8.1. Partnered Initiatives
8.2.8.2. In-House Initiatives

8.2.9. Sanofi
8.2.9.1. Partnered Initiatives
8.2.9.2. In-House Initiatives

9. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS: MARKET LANDSCAPE
9.1. Chapter Overview
9.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
9.2.1. Analysis by Type of Equipment
9.2.2. Analysis by Type of Manufacturing Process
9.2.3. Analysis by Stage of Bioprocess
9.2.4. Analysis by Scale of Operation

9.3. Continuous Manufacturing Equipment Providers for Biologics
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Prominent Continuous Manufacturing Equipment Providers

10. COST SAVING ANALYSIS
10.1. Chapter Overview
10.2 Technologies Involved in Continuous and Semi-Continuous Bioprocessing
10.3 Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing
10.3.1. Potential Cost Savings in Upstream Processes
10.3.2. Potential Cost Savings in Downstream Processes

10.4. Key Assumptions and Methodology
10.5 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocesses, 2021-2030
10.6 Concluding Remarks

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3.1. Global, Continuous and Semi-Continuous Bioprocessing Capacity
11.3.2. Analysis by Company Size
11.3.3. Analysis by Type of Manufacturer
11.3.4. Analysis by Company Size and Type of Manufacturer
11.3.4. Analysis by Scale of Operation
11.3.5. Analysis by Location of Headquarters
11.3.6. Analysis by Location of Continuous and Semi-Continuous Bioprocessing Facilities

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030
12.3.1. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.3.2. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size
12.3.3. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.3.4. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess
12.3.5. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

12.4. Continuous Upstream Bioprocessing Market, 2021-2030
12.4.1. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.4.2. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size
12.4.3. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.4.4. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

12.5. Continuous Downstream Bioprocessing Market, 2021-2030
12.5.1. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.5.2. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size
12.5.3. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.5.4. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

13. CONCLUSION

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. AstraZeneca
14.2.1. Overview of Company / Organization 
14.2.2. Interview Transcript: Jon Coffman, Senior Director of Bioprocess Technology and Engineering

14.3. Enzene Biosciences
14.3.1. Overview of Company / Organization 
14.3.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer

14.4. Albany College of Pharmacy and Health Sciences
14.4.1. Overview of Company / Organization 
14.4.2. Interview Transcript: Ehsan Mahdinia, Assistant Professor

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Advantages of Continuous Bioprocessing
Figure 4.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Figure 4.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Figure 4.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Figure 4.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Figure 4.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Figure 4.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Figure 4.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Facilities of Innovators
Figure 4.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Figure 4.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Figure 4.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Figure 4.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Figure 4.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Figure 4.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Figure 4.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Figure 4.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Figure 8.1 Continuous Manufacturing Initiatives: AbbVie
Figure 8.2 Continuous Manufacturing Initiatives: Amgen
Figure 8.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
Figure 8.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
Figure 8.5 Continuous Manufacturing Initiatives: Merck
Figure 8.6 Continuous Manufacturing Initiatives: Novartis
Figure 8.7 Continuous Manufacturing Initiatives: Pfizer
Figure 8.8 Continuous Manufacturing Initiatives: Roche
Figure 8.9 Continuous Manufacturing Initiatives: Sanofi
Figure 9.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Figure 9.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Figure 9.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Figure 9.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Figure 9.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Figure 9.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Figure 9.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Figure 9.8 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Figure 10.1 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Figure 10.2 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocess Techniques, 2021-2030 (USD Billion)
Figure 11.1 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Figure 11.2 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Figure 11.3 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Figure 11.4 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Figure 11.5 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Figure 11.6 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Figure 11.7 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Figure 12.1 Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.2 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.3 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.4 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.5 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Figure 12.6 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.7 Continuous Upstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.8 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.9 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.10 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.11 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.12 Continuous Downstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.13 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.14 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.15 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.16 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 13.1 Concluding Remarks: Market Landscape
Figure 13.2 Concluding Remarks: Capacity Analysis
Figure 13.3 Concluding Remarks: Recent Expansions
Figure 13.4 Concluding Remarks: Cost Saving Analysis
Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis for Continuous and Semi-Continuous Bioprocessing Market

List Of Tables

Table 3.1 Early Adopters of Continuous Bioprocess Technology
Table 3.2 Batch Processing Technique versus Continuous Processing Technique: Comparison of Characteristics
Table 4.1 List of Companies with Expertise in Continuous and Semi-Continuous Bioprocessing
Table 4.2 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Scale of Operation
Table 4.3 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Type of Facility and Type of Bioreactor
Table 4.4 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Stage of Bioprocess
Table 4.5 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Primary Continuous and Semi-Continuous Bioprocessing
Table 4.6 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Secondary Continuous and Semi-Continuous Bioprocessing
Table 4.7 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Types of Biologics Manufactured
Table 4.8 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Production Capacity
Table 5.1 AGC Biologics: Company Snapshot
Table 5.2 AGC Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.3 AGC Biologics: Recent Developments and Future Outlook
Table 5.4 Biogen: Company Snapshot
Table 5.5 Biogen: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.6 Biogen: Recent Developments and Future Outlook
Table 5.7 Bristol-Myers Squibb: Company Snapshot
Table 5.8 Bristol-Myers Squibb: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 5.10 Sanofi Genzyme: Company Snapshot
Table 5.11 Sanofi Genzyme: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.12 Sanofi Genzyme: Recent Developments and Future Outlook
Table 6.1 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.2 FUJIFILM Diosynth Biotechnologies: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.3 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.4 Merck KGaA: Company Snapshot
Table 6.5 Merck KGaA: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.6 Merck KGaA: Recent Developments and Future Outlook
Table 6.7 Novasep: Company Snapshot
Table 6.8 Novasep: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.9 Novasep: Recent Developments and Future Outlook
Table 6.10 UCB Pharma: Company Snapshot
Table 6.11 UCB Pharma: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.12 UCB Pharma: Recent Developments and Future Outlook
Table 7.1 Enzene Biosciences: Company Snapshot
Table 7.2 Enzene Biosciences: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.3 Enzene Biosciences: Recent Developments and Future Outlook
Table 7.4 WuXi Biologics: Company Snapshot
Table 7.5 WuXi Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.6 WuXi Biologics: Recent Developments and Future Outlook
Table 8.1 AbbVie: Partnered Initiatives
Table 8.2 AbbVie: In-House Initiatives
Table 8.3 Amgen: Partnered Initiatives
Table 8.4 Amgen: In-House Initiatives
Table 8.5 Bristol-Myers Squibb: Partnered Initiatives
Table 8.6 Bristol-Myers Squibb: In-House Initiatives
Table 8.7 GlaxoSmithKline: Partnered Initiatives
Table 8.8 GlaxoSmithKline: In-House Initiatives
Table 8.9 Merck: Partnered Initiatives
Table 8.10 Merck: In-House Initiatives
Table 8.11 Novartis: Partnered Initiatives
Table 8.12 Novartis: In-House Initiatives
Table 8.13 Pfizer: Partnered Initiatives
Table 8.14 Pfizer: In-House Initiatives
Table 8.15 Roche: Partnered Initiatives
Table 8.16 Roche: In-House Initiatives
Table 8.17 Sanofi: Partnered Initiatives
Table 8.18 Sanofi: In-House Initiatives
Table 9.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Bioprocess
Table 9.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
Table 9.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
Table 10.1 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Upstream Process
Table 10.2 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential of AcuSyst Perfusion Bioreactors
Table 10.3 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Downstream Process
Table 11.1 Global Continuous and Semi-Continuous Bioprocessing Capacity: Average Upstream Capacity by Company Size (Sample Data Set)
Table 14.1 AstraZeneca: Company / Organization Snapshot
Table 14.2 Enzene Biosciences: Company / Organization Snapshot
Table 14.3 Albany College of Pharmacy and Health Sciences: Company / Organization Snapshot
Table 15.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Table 15.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Table 15.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Table 15.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Table 15.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Table 15.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Table 15.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Innovators
Table 15.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Table 15.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Table 15.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Table 15.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Table 15.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Table 15.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Table 15.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Table 15.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Table 15. 16 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Table 15.17 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Table 15.18 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Table 15.19 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Table 15.20 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Table 15.21 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Table 15.22 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Table 15.23 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Table 15.24 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Table 15.25 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing Techniques, 2021-2030 (USD Billion)
Table 15.26 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Table 15.27 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Table 15.28 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Table 15.29 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Table 15.30 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Table 15.31 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Table 15.32 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Table 15.33 Overall Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030
Table 15.34 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.35 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.36 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.37 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Table 15.38 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.39 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.40 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.41 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.42 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.43 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.44 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.45 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.46 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.47 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.48 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)

List Of Companies

  1. 3D Biotek
  2. 3P Biopharmaceuticals
  3. AbbVie 
  4. ABL Europe
  5. Abzena 
  6. Accenture 
  7. AGC Biologics
  8. AIM ImmunoTech 
  9. Alexanderwerk 
  10. Alvotech
  11. Amgen
  12. AmpTec
  13. Applikon Biotechnology
  14. Aprogen
  15. AstraZeneca
  16. Avid Bioservices (formerly Peregrine Pharmaceuticals)
  17. Baxter
  18. Bayer
  19. bbi-biotech
  20. BIBITEC
  21. BINEX
  22. Biogen
  23. BioMarin Pharmaceutical
  24. Bionova Scientific
  25. BiosanaPharma 
  26. Bio-Thera Solutions 
  27. Biovian
  28. bluebird bio
  29. Boehringer Ingelheim BioXcellence 
  30. Bonumose 
  31. Bristol-Myers Squibb
  32. Changchun High & New Technology 
  33. Canton Biologics
  34. CCHT Biopharmaceutical
  35. Celgene 
  36. Cell and Gene Therapy Catapult 
  37. Cell Culture Company
  38. CELLEC Biotek
  39. Celonic
  40. Centre for Process Innovation (CPI)
  41. Cerbios-Pharma
  42. CMAC 
  43. Cobra Biologics 
  44. Codiak BioSciences
  45. Coperion
  46. Creative Biolabs
  47. CSL Behring
  48. Cytiva
  49. Cytovance Biologics
  50. DCI-Biolafitte 
  51. DEVEX Verfahrenstechnik
  52. DSM Pharmaceutical
  53. Durham University
  54. Eli Lilly
  55. Engage Therapeutics (Acquired by UCB Pharma)
  56. Enzene Biosciences
  57. Eppendorf
  58. Esco Aster
  59. ETH Zurich
  60. EV Biologics
  61. Evotec
  62. Exelixis 
  63. Exothera
  64. Forbius 
  65. FUJIFILM Diosynth Biotechnologies
  66. Gallus BioPharmaceuticals (Acquired by Patheon)
  67. G-CON Manufacturing
  68. GEA 
  69. Genzyme
  70. Global BioTherapeutics (GBT)
  71. Glycotope 
  72. Goodwin Biotechnology
  73. GTP Technology
  74. HAL Allergy
  75. HALIX 
  76. Handl Therapeutics
  77. Hemispherx Biopharma
  78. HJB
  79. Horizon Therapeutics 
  80. Janssen Pharmaceuticals
  81. Johnson & Johnson 
  82. Just-Evotec Biologics
  83. KBI Biopharma
  84. Kemwell Biopharma
  85. Kiadisto 
  86. Kymab
  87. Lonza
  88. Luina Bio
  89. Lupin
  90. MabSpace Biosciences 
  91. Medix Biochemica
  92. Merck
  93. Merck KGaA
  94. Microsoft 
  95. MolMed 
  96. Mycenax Biotech
  97. MyoKardia (acquired by Bristol-Myers Squibb)
  98. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
  99. National Resilience 
  100. Natrix Separations (Acquired by Merck)
  101. Nightstar Therapeutics (acquired by Biogen)
  102. Novartis
  103. Novasep
  104. Novavax 
  105. Novo Nordisk
  106. Ology Bioservices 
  107. OmniBRx Biotechnologies
  108. OXGENE (Acquired by WuXi AppTec)
  109. PacificGMP
  110. Pall Biotech
  111. Pall Life Sciences
  112. Pfizer
  113. Pierre Fabre 
  114. PIERRE GUERIN
  115. Polymun Scientific
  116. ProBioGen
  117. Rentschler Biopharma
  118. Repligen 
  119. Sage Therapeutics 
  120. Samsung Biologics
  121. Sangamo Therapeutics 
  122. Sanofi Genzyme
  123. Sartorius
  124. Semba Biosciences
  125. Servier
  126. Shire
  127. Sturtevant
  128. Syngene
  129. Synthecon
  130. TA Instruments
  131. ThalesNano
  132. The Rockefeller University 
  133. Thermo Fisher Scientific
  134. Tidal Therapeutics (Acquired by Sanofi)
  135. Transcenta 
  136. Translate Bio
  137. UCB Pharma
  138. UIC College of Pharmacy
  139. Universitas Indonesia 
  140. University of Strathclyde
  141. Vapourtec
  142. Vigene Biosciences 
  143. WuXi Biologics
  144. WuXi STA 
  145. XPure
  146. YMC Process Technologies

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com